Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.
Rapamycin suppressed peritoneal tumor growth and strengthened tumor suppression with 5-FU and/or oxaliplatin in orthotopic models.
REPURPOSED MEDICINE · CELLULAR GROWTH · METABOLIC SIGNALING
Rapamycin, Sirolimus and mTOR Inhibition in Cancer
The mTOR pathway integrates nutrient, growth and survival signals. Rapamycin, sirolimus analogues and related mTOR inhibitors have been studied across sarcoma, renal cancer, neuroendocrine tumors, leukemia and other malignancies.
Rapamycin, Sirolimus and mTOR Inhibition in CancerReview the research in the context of your diagnosis
Share your diagnosis, current treatment and the questions you want the clinical team to consider.
Rapamycin, Sirolimus and mTOR Inhibition in Cancer
Speak With Our Patient Care Team
Tell us what you are facing and what you hope to understand. The team will follow up personally.
*
Required fields
Prefer to speak with someone now?
1-800-923-7878
- Your cancer type, stage and current plan are reviewed together
- The exact medicine, dose, timing and goals can be discussed
- Questions before scheduling are always welcome
PHYSICIAN-DIRECTED INTEGRATIVE CARE
Research organized around the cancer and the person
Sunridge approaches mTOR-directed therapy as prescription medicine requiring diagnosis-specific review, medication reconciliation and monitoring. The library includes rapamycin biology alongside clinical research on related mTOR inhibitors.
mTORC1 and mTORC2 signaling
Cell growth and apoptosis
Tumor response and disease control
Biomarker-guided treatment
SEARCH THE LIBRARYOpen study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed →
Studies grouped by cancer type
Open study on PubMed →
Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.
Dual mTORC1/2 inhibition reduced colorectal-cancer growth, activated autophagy, inhibited HT-29 xenografts and improved survival in the reported model.
Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.
Rapamycin reduced proliferation in sensitive colorectal-cancer cells, while broader mTOR suppression increased apoptosis and inhibited xenograft growth.
Machine Learning-Based Predictive Modeling Maximizes the Efficacy of mTOR/p53 Co-Targeting Therapy Against AML.
mTOR inhibition combined with p53 activation reduced MYC and MCL1 and promoted cell-cycle arrest and apoptosis in acute-myeloid-leukemia research.
Biological Aspects of mTOR in Leukemia.
A review describes the central role of mTOR in leukemia metabolism, growth, proliferation and survival and summarizes therapeutic targeting.
Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
Everolimus with carboplatin and paclitaxel produced a 45% response rate and 74% disease-control rate in metastatic large-cell neuroendocrine lung carcinoma.
Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.
In the RADIANT-4 lung subgroup, median progression-free survival improved and tumor shrinkage occurred more often with everolimus.
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
RADIANT-3 reported a 6.4-month improvement in median progression-free survival with everolimus in advanced pancreatic neuroendocrine tumors.
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
RADIANT-4 reported median progression-free survival of 11.0 months with everolimus versus 3.9 months with placebo in lung or gastrointestinal neuroendocrine tumors.
Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update.
Final AMPECT follow-up reported a 38.7% response rate, two complete responses and a median response duration of 39.7 months.
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors.
The AMPECT phase II trial reported a 39% objective response rate with nab-sirolimus in malignant PEComa, including complete and partial responses.
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
A randomized phase III study established clinical activity for temsirolimus in advanced renal-cell carcinoma.
Everolimus.
Everolimus research in previously treated renal-cell carcinoma reported longer median progression-free survival than placebo.
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
Ridaforolimus maintenance produced a modest but statistically significant progression-free-survival improvement after chemotherapy benefit.
No studies match those filters. Clear a filter or try a broader search.
CONNECTED RESEARCH
Explore the other medicine libraries
Discuss this research in the context of your case
Our Patient Care Team can help you begin a conversation about your diagnosis, current oncology plan, goals, medicines and integrative options used at Sunridge.